The Science of Longevity: What Peptide Research Reveals

*IMPORTANT DISCLAIMER: The research discussed in this article is for educational purposes only. The compounds and interventions mentioned below are subjects of ongoing scientific research and are not approved by the FDA for the purpose of extending lifespan or treating aging. This is not medical advice. Nothing here constitutes a recommendation to use any specific compound. Always consult a licensed healthcare provider before making any changes to your health regimen.*

---

Longevity peptides research has transformed our understanding of aging. Over the past two decades, researchers have mapped many of the molecular pathways that drive cellular aging, and have identified compounds that appear to influence those pathways.

The science is still evolving. Most longevity research has been conducted in animal models, and translating those findings to humans is complex. But the pace of discovery is accelerating, and the questions being asked are increasingly precise.

This article explores what research currently suggests about some of the most studied longevity-related compounds: NAD+ precursors, rapamycin, and metformin. It also looks at how peptides - small chains of amino acids - fit into the broader longevity research landscape.

---

Why Aging Research Has Accelerated

For most of medical history, aging was treated as inevitable and largely beyond intervention. That view has shifted significantly since the identification of what researchers call the "hallmarks of aging" - a framework describing nine interconnected cellular processes that drive age-related decline.

A landmark 2013 paper in Cell by Lopez-Otin and colleagues described these hallmarks, including genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, mitochondrial dysfunction, cellular senescence, and others ([PMID: 23746838](https://pubmed.ncbi.nlm.nih.gov/23746838/)). The paper established that aging, at a molecular level, is not random - it follows recognizable patterns that may be modifiable.

This framework helped channel research toward specific, testable interventions. Today, several compounds are in human clinical trials aimed at targeting one or more of these hallmarks.

---

NAD+ and the Energy Currency of Aging

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell of your body. It plays a central role in energy metabolism and is a required substrate for a class of proteins called sirtuins, which help regulate DNA repair, gene expression, and stress responses.

Research indicates that NAD+ levels decline significantly with age. A 2013 study in Cell found that restoring NAD+ levels in aging mice reversed aspects of muscle aging and improved energy metabolism ([PMID: 23663781](https://pubmed.ncbi.nlm.nih.gov/23663781/)).

Precursors to NAD+ - particularly nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) - have been studied as approaches to raising NAD+ levels in humans.

A 2018 human trial published in Nature Communications found that oral NR supplementation was safe and effectively raised NAD+ levels in healthy older adults ([PMID: 29184669](https://pubmed.ncbi.nlm.nih.gov/29184669/)). Several subsequent studies have confirmed NAD+ precursors can raise circulating NAD+ levels in humans.

Whether raising NAD+ levels translates to meaningful clinical benefits in humans remains an active area of investigation. Studies suggest potential benefits in areas like muscle function, cardiovascular health, and metabolic parameters - but larger, longer-term trials are ongoing.

*Research is ongoing. These findings are not clinical recommendations. Consult your healthcare provider about any supplementation.*

---

Rapamycin: mTOR Inhibition and Lifespan Extension

Rapamycin is perhaps the most studied longevity compound in animal research. It inhibits mTOR (mechanistic target of rapamycin), a cellular pathway that regulates growth, metabolism, and autophagy - the cellular process of clearing out damaged components.

The evidence in animal models is striking. A landmark 2009 study published in *Nature* found that rapamycin extended the median and maximum lifespan of mice by 9-14%, even when treatment was started late in life (equivalent to a 60-year-old human beginning treatment) ([PMID: 19587680](https://pubmed.ncbi.nlm.nih.gov/19587680/)). This was a first - demonstrating that a pharmacological intervention could extend lifespan even when initiated in late middle age.

Subsequent studies in mice have shown even greater lifespan extension with earlier or intermittent treatment, and positive effects on multiple markers of aging.

In humans, rapamycin is FDA-approved for use as an immunosuppressant in organ transplant recipients and for certain rare conditions. It is not approved for longevity or anti-aging use. Researchers are currently investigating whether intermittent, low-dose rapamycin can produce benefits in healthy aging adults without the immunosuppressive effects seen at transplant doses.

The PEARL trial - a randomized controlled trial of low-dose rapamycin in healthy adults - is among the ongoing studies examining this question. Interim findings suggest low-dose rapamycin is generally well-tolerated in healthy adults, with ongoing evaluation of biomarkers of aging.

*Important: Rapamycin has significant side effects and drug interactions at therapeutic doses. Its use for longevity in healthy individuals remains investigational. Never self-administer rapamycin or any prescription compound without clinician oversight.*

---

Metformin: From Diabetes Drug to Longevity Candidate

Metformin is a widely prescribed generic medication for type 2 diabetes. It works primarily by reducing glucose production in the liver and improving insulin sensitivity.

Observational data from large diabetic populations suggested something unexpected: people taking metformin appeared to have lower rates of cancer, cardiovascular disease, and overall mortality compared to what would be expected - and in some analyses, better outcomes than non-diabetics not taking metformin.

A notable 2014 study in Diabetologia found that people with type 2 diabetes on metformin had lower all-cause mortality than matched non-diabetic controls ([PMID: 24816585](https://pubmed.ncbi.nlm.nih.gov/24816585/)).

This prompted serious investigation into whether metformin might target aging biology independently of its glucose-lowering effects. Proposed mechanisms include activation of AMPK (an energy-sensing enzyme), reduction of mTOR signaling, and reduction of oxidative stress and inflammation.

The TAME trial (Targeting Aging with Metformin) - a large, multi-center randomized controlled trial - is specifically designed to test whether metformin can delay the onset of age-related diseases in non-diabetic older adults. This is the first clinical trial designed to use aging itself (rather than a specific disease) as the primary endpoint - a landmark moment for longevity research.

Results from TAME are expected to provide significant clarity on whether metformin's apparent benefits in diabetic populations translate to non-diabetic aging adults.

*Metformin is a prescription medication with side effects and contraindications. Its use for longevity in non-diabetic individuals remains investigational.*

---

Peptides in Longevity Research

Peptides - short chains of amino acids - represent another area of active longevity research. Several classes of peptides have attracted scientific interest.

Epitalon (Epithalon)

Epitalon is a synthetic tetrapeptide (four amino acids) that has been studied primarily by Russian researchers. Research suggests it may influence telomere length and activate telomerase, the enzyme that can rebuild telomere ends.

Animal studies and some early human research suggest Epitalon may have antioxidant properties and influence circadian rhythms and immune function. A series of studies by Vladimir Khavinson and colleagues over several decades documented various effects in animal and human populations (though these studies have not been widely replicated in Western research settings).

The research base is interesting but limited in size and scope compared to metformin or rapamycin. Larger, independently conducted trials would be needed to draw firm conclusions.

BPC-157 and Tissue Repair

BPC-157 (body protection compound-157) is a synthetic peptide derived from a protein found in gastric juice. Animal research has shown it may promote healing in various tissues - tendons, ligaments, gut lining, and muscle - through angiogenesis (new blood vessel formation) and influence on growth hormone receptors.

A 2018 review in Current Neuropharmacology summarized animal data showing neuroprotective, anti-inflammatory, and tissue-regenerative effects ([PMID: 27753435](https://pubmed.ncbi.nlm.nih.gov/27753435/)).

No large-scale human clinical trials have established BPC-157's efficacy or safety in humans. It is not FDA-approved.

Thymosin Alpha-1

Thymosin alpha-1 is a naturally occurring peptide produced by the thymus gland, which plays a key role in immune function. Research suggests it may enhance T-cell function and immune response. It has been used clinically in some countries for hepatitis and is being studied for immune modulation.

Research in aging populations suggests thymosin alpha-1 levels decline with age alongside thymus involution, and studies indicate immune-boosting effects in older adults ([PMID: 26403784](https://pubmed.ncbi.nlm.nih.gov/26403784/)).

---

What the Research Means - and What It Does Not

The longevity research landscape is genuinely exciting. There are more plausible biological targets, more active clinical trials, and more serious scientific attention on aging as a modifiable process than at any prior point in history.

But several important caveats apply:

Most compelling data comes from animal models. Mice and humans differ in fundamental ways. Many interventions that extended lifespan in rodents have not translated to humans.

Human trials are still early. The TAME trial with metformin is the first trial designed to target aging itself - it has not yet reported final results. Trials of other compounds are similarly early-stage.

Individual risk profiles matter enormously. What is appropriate investigation in a healthy 40-year-old researcher may be inappropriate for someone with chronic conditions, other medications, or different health goals.

"Promising research" is not the same as "proven effective." This distinction matters.

Prescriva is building toward longevity and peptide programs as a future offering, designed for people who want clinician-supervised access to the most evidence-backed approaches available.

Want to be among the first to know when Prescriva's longevity program launches? Join the waitlist for upcoming longevity programs.

---

The Bottom Line

Longevity research has moved from the fringe to the mainstream of serious biomedical science. NAD+ precursors, rapamycin, metformin, and various peptides are being studied through rigorous scientific methods, and early findings are generating genuine excitement among researchers.

The science is not settled. The gap between animal data and proven human benefit remains significant for most interventions. But the pace of research is accelerating, and the next decade is likely to bring substantially more clarity.

What remains constant: the need for clinician oversight, honest evaluation of the evidence, and individualized decision-making. Longevity is not a shortcut - it is a discipline.

---

*This article is for educational and research purposes only. The compounds discussed are subjects of ongoing research and are not FDA-approved for longevity, anti-aging, or the prevention or treatment of any disease. Prescriva does not sell or prescribe the research compounds discussed in this article.*

*Do not attempt to self-administer any research compound. Nothing in this article constitutes medical advice or a recommendation to use any specific compound. Consult a licensed healthcare provider before making any changes to your health regimen. Individual responses to any intervention vary significantly.*

---

References

1. Lopez-Otin C, et al. The hallmarks of aging. *Cell.* 2013;153(6):1194-1217. [PMID: 23746838](https://pubmed.ncbi.nlm.nih.gov/23746838/)
2. Gomes AP, et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. *Cell.* 2013;155(7):1624-1638. [PMID: 23663781](https://pubmed.ncbi.nlm.nih.gov/23663781/)
3. Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. *Nat Commun.* 2018;9(1):1286. [PMID: 29184669](https://pubmed.ncbi.nlm.nih.gov/29184669/)
4. Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature.* 2009;460(7253):392-395. [PMID: 19587680](https://pubmed.ncbi.nlm.nih.gov/19587680/)
5. Bannister CA, et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched non-diabetic controls. *Diabetologia.* 2014;57(12):2489-2496. [PMID: 24816585](https://pubmed.ncbi.nlm.nih.gov/24816585/)
6. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. *Curr Pharm Des.* 2011 (also see [PMID: 27753435](https://pubmed.ncbi.nlm.nih.gov/27753435/) for CNS review)
7. Goldstein AL, et al. Thymosin alpha 1: chemistry, biology and clinical applications. *Front Immunol.* 2012;3:129. (see also [PMID: 26403784](https://pubmed.ncbi.nlm.nih.gov/26403784/))